Risk of major adverse cardiovascular events after SARS-CoV-2 infection in British Columbia: a population-based study

Abstract

BackgroundCOVID-19 is associated with increased risk of post-acute cardiovascular outcomes. Population-based evidence for long periods of observation is still limited. MethodsThis population-based cohort study was conducted using data (2020-2001) from the British Columbia COVID-19 Cohort. The exposure of interest was SARS-CoV-2 infection, identified through reverse transcription–polymerase chain reaction (RT-PCR) assay. Individuals who tested positive (exposed) on RT-PCR were matched to negative controls (unexposed), on sex, age, and RT-PCR collection date, in a 1:4 ratio. Outcomes of interest were incident major adverse cardiovascular events and acute myocardial infarction, identified more than 30 days after RT-PCR collection date. The association between SARS-CoV-2 infection and cardiovascular risk was assessed through multivariable survival models. Population attributable fractions were computed from Cox models. Results: We included 649,320 individuals: 129,864 exposed and 519,456 unexposed. The median duration of follow-up was 260 days; 1,786 events (0·34%) took place among the unexposed, and 702 (0·54%) in the exposed. The risk of major adverse cardiovascular events was higher in the exposed (adjusted HR [aHR]:1·34; 95%CI:1·22-1·46), with greater risk observed in those who were hospitalized (aHR:3·81; 95%CI:3·12-4·65) or required ICU admission (aHR:6·25; 95%CI:4·59-8·52) compared to the unexposed group. The fraction of cardiovascular events attributable to SARS-CoV-2 was 7·04% (95%CI:4·67-9·41%). Comparable results were observed for acute myocardial infarction. ConclusionsSARS-CoV-2 infection was associated with higher cardiovascular risk with graded increase across the acute COVID-19 severity, contributing to 7% of incident major adverse cardiovascular events. These findings suggest that long-term monitoring of cardiovascular risk is required in COVID-19 survivors.